Arvinas (United States)
company in New Haven, United States
ARVN Nasdaq
SEC CIK 1655759
Follow Arvinas (United States)
Weekly email: filings, results
Revenue, last quarter
$500K
−98.8% vs same quarter last year
Net income
−$53.9M
−53.6% vs same quarter last year
EPS, diluted
−$0.82
−70.8% vs same quarter last year
Operating cash flow
−$10.4M
+82.4% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $262.6M | −$81M |
| FY24 | $263.4M | −$199M |
| FY23 | $78.5M | −$367M |
| FY22 | $131.4M | −$283M |
| FY21 | $46.7M | −$191M |
| FY20 | $21.8M | −$119.3M |
| FY19 | $18.3M | −$70.3M |
| FY18 | $14.3M | −$41.5M |
| FY17 | $7.6M | −$24M |
| FY16 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | −45.1% | −30.8% |
| FY24 | −95% | −75.6% |
| FY23 | −511.5% | −467.5% |
| FY22 | −200.3% | −215.4% |
| FY21 | −403.4% | −409% |
| FY20 | −554.1% | −547.2% |
| FY19 | −281.4% | −384.2% |
| FY18 | −306.3% | −290.1% |
| FY17 | −326.7% | −317.3% |
| FY16 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$275.7M |
| FY24 | −$261.1M |
| FY23 | −$350.7M |
| FY22 | −$280.3M |
| FY21 | $554.7M |
| FY20 | −$96.1M |
| FY19 | −$46.9M |
| FY18 | −$18.9M |
| FY17 | $4.1M |
| FY16 | - |
Show the numbers
| Year | Buybacks |
|---|---|
| FY25 | $91.9M |
| FY24 | $0 |
| FY23 | $0 |
| FY22 | - |
| FY21 | - |
| FY20 | - |
| FY19 | - |
| FY18 | - |
| FY17 | - |
| FY16 | - |
- Arvinas (United States)
- Healthcare median
Show the numbers
| Year | Arvinas (United States) | Healthcare median |
|---|---|---|
| FY25 | −30.8% | −30.6% |
| FY24 | −75.6% | −47% |
| FY23 | −467.5% | −58% |
| FY22 | −215.4% | −80.4% |
| FY21 | −409% | −71.8% |
| FY20 | −547.2% | −62.2% |
| FY19 | −384.2% | −46.2% |
| FY18 | −290.1% | −49.6% |
| FY17 | −317.3% | −45.9% |
| FY16 | - | −36% |